Skip to main content
PMC home page
OncoTargets and Therapy logoLink to OncoTargets and Therapy
. 2016 Oct 7;9:6083–6091. doi: 10.2147/OTT.S118481

IL-10 -1082A/G, -592C/A, and -819T/C polymorphisms in association with lung cancer susceptibility: a meta-analysis

Liang Liu 1, Feng Zheng 2,✉
PMCID: PMC5065258  PMID: 27785055

Abstract

Numerous studies have examined the association between interleukin-10 (IL-10 -1082A/G, -592C/A, and -819T/C) gene polymorphisms and risk of lung cancer, but these have revealed inconsistent results. The aim of this study was to clarify the relationship between these polymorphisms and the risk of lung cancer by performing a meta-analysis. The published literature concerning IL-10 polymorphisms and lung cancer risk were retrieved by systematically searching PubMed, Embase, Web of Science, China National Knowledge Infrastructure, WanFang, and Database of Chinese Scientific and Technical Periodicals (VIP) database. Statistical analysis was conducted with Stata 12.0 software. A total of ten published articles comprising of 19 studies were selected, including seven studies (1,960 controls and 1,321 cases) for IL-10 -1082A/G, seven studies (2,613 controls and 1,839 cases) for IL-10 -592C/A, and five studies (1,558 controls and 926 cases) for IL-10 -819T/C. This study found that the IL-10 -1082A/G and -592C/A polymorphisms were significantly associated with the risk of lung cancer in the overall analysis. When stratified by ethnicity, significantly increased risks were observed for IL-10 -1082A/G, -592C/A, and -819T/C polymorphisms in Asians (for -1082A/G, AA vs [AG + GG]: odds ratio [OR] =1.20, confidence interval [CI] =1.05–1.39, P<0.05; for C-592A, C vs A, OR =1.36, CI =1.20–1.53, P<0.05; CC vs AA, OR =1.85, CI =1.45–2.37, P<0.05; CC vs [CA + AA], OR =1.36, CI =1.15–1.61, P<0.05; for -819T/C, T vs C: OR =1.21, CI =1.06–1.38, P<0.05; TT vs CC, OR =1.54, CI =1.18–2.01, P<0.05; [TT + TC] vs CC, OR =1.51, CI =1.17–1.95, P<0.05). Moreover, the data indicated that there was a significant association between IL-10 -819T/C polymorphism and non-small-cell lung cancer risk. No significant publication bias was detected under the four genetic models (allele model, homozygous model, dominant model, and recessive model) in this meta-analysis. On the basis of these 19 studies, this study found that the IL-10 -1082A/G and -819T/C polymorphisms might have a significant association with risk of lung cancer in Asian populations.

Keywords: interleukin-10, lung neoplasms, polymorphism, susceptibility, meta-analysis

Introduction

Lung cancer is one of the most commonly diagnosed tumors and continually leads to many deaths worldwide.1 There were an estimated 1.8 million new cases of lung cancer in 2012, which occurred in the developing countries, accounting for 58% of the total cases. An estimated 1,987,909 new cases of lung cancer were diagnosed and 1,732,185 deaths were due to lung cancer in 2012. Moreover, lung cancer is the most common tumor in males.2 The incidence of lung cancer is still obviously increasing.3 The 5-year survival rate for lung cancer patients was only 16% in the past four decades, and the main obstacle in improving lung cancer prognosis was delayed diagnosis.4 There are many reasons for the occurrence of lung cancer, but the major external risk factor was easily identified – cigarette smoking. It has been reported that current smokers are approximately 20 times more likely than never smokers to develop lung cancer.5,6 Thus, smoking cessation is very important for public health. In addition, early detection and diagnosis play a crucial role in decreasing the mortality of lung cancer. Survival of lung cancer patients undergoing lung resection was more than 80%, which suggested that early detection and diagnosis helped immensely in the early treatment of lung cancer.7,8 Increasing evidence has indicated that polymorphisms of numerous susceptible genes play a significant association in the development of lung cancer. Thus, these polymorphisms could be useful as biomarkers for lung cancer detection.

Interleukin-10 (IL-10) cytokine, which is essential for TH2 responses, plays a central role in anti-inflammation and is also capable of blocking tumor immune surveillance to inhibit T-cell immunity.9 A recent study has shown that the expression of IL-10 was associated with progression of tumors including lung cancer.10 Some genetic polymorphisms of IL-10 gene, especially in the promoter region, could affect the expression of gene-encoded proteins associated with lung cancer susceptibility and prognosis.11 Three SNPs at positions -1082, -592, and -819 of IL-10 gene promoter have been reported to be associated with expression of IL-10 gene.12 Moreover, many individual studies have investigated the role of IL-10 -1082A/G, -592C/A, and -819T/C polymorphisms in lung cancer risk. Nevertheless, the results of these studies remained ambiguous and inconclusive owing to the reduced power of single studies. In this study, an updated meta-analysis was performed to estimate the effect of IL-10 -1082A/G, -592C/A, and -819T/C polymorphisms on lung cancer risk.

Material and methods

Literature search strategy

The databases of PubMed, Embase, Web of Science, China National Knowledge Infrastructure, WanFang, and Database of Chinese Scientific and Technical Periodicals (VIP) were searched up to July 2016 to identify relevant studies published concerning the correlation of IL-10 -1082A/G, -592 C/A, and -819T/C polymorphisms with lung cancer risk. The following MESH terms and their synonyms were used: (“Lung Neoplasms” [MESH] or “lung cancer” or “lung tumor” or “lung carcinoma”) and (“Interleukin-10” or “IL-10”). Language restriction was not applied in the process of retrieval. The reference lists of retrieved article were hand searched.

Inclusion criteria and exclusion criteria

The following inclusion criteria were used: 1) studies investigating the association between IL-10 -1082A/G, -592C/A, and -819T/C polymorphisms and lung cancer risk; 2) studies with a case–control or cohort design; 3) studies with sufficient genotyping data available for calculation of odds ratios (ORs) and 95% confidence intervals (95% CIs); and 4) studies performed in humans. The exclusion criteria were as follows: 1) not a case–control or cohort study, 2) studies without available genotype data, 3) studies with duplicate data, and 4) meta-analysis and reviews.

Quality score assessment

The Newcastle–Ottawa scale was used to assess the quality of studies included. Two investigators independently calculated the score of each study. The scores ranged from 0 to 9, and a score of ≥7 indicated a high quality study.

Data extraction

Two investigators independently searched articles and extracted the original data according to the inclusion criteria and exclusion criteria. The extracted information from each eligible study included the following: 1) the first author’s name, 2) year of publication, 3) ethnicity, 4) source of controls, 5) number of cases and controls, and 6) genotype frequencies. Disagreement in data extraction was settled by consulting with the third investigator.

Statistical analysis

The strength of association between IL-10 -1082A/G, -592C/A, and -819T/C polymorphisms and lung cancer risk was evaluated by calculating crude ORs and 95% CIs under an allele, a homozygous, a dominant, and a recessive model, respectively. Chi-square-based Q-test and I2 statistic test were performed to evaluate the heterogeneity assumption. A random-effects model (the DerSimonian and Laird method) was used to calculate the crude ORs of each study in case of P<0.05 or I2>50%, whereas a fixed-effects model (the Mantel–Haenszel method) was used if heterogeneity did not exist.13,14 Potential publication bias was evaluated using Begg’s funnel plots and Egger’s test. Sensitivity analysis was conducted to estimate the stability of the results by omitting each single study. The overall analysis and stratified analysis were performed using Stata 12.0 software (Stata Corp LP, College Station, TX, USA).

Results

Characteristics of published studies

Based on the inclusion criteria, a total of 372 publications were obtained on literature searching. After removing the articles that did not deal with the association of IL-10 polymorphism with lung cancer risk, reviews, and meta-analysis, 14 were left for further analysis. After further evaluation by reading full texts, four publications were excluded because of insufficient data on IL-10 genotype. Finally, 10 articles with 19 studies that investigated the correlation of IL-10 -1082A/G, -592C/A, and -819T/C polymorphisms with lung cancer risk were used for the further statistical analysis. Of these, eleven studies were conducted in Asians and eight studies were performed in Caucasians. In addition, eight publications were in English and two publications were in Chinese. The characteristics of all the studies included are listed in Table 1 and shown in Figure 1.

Table 1.

Characteristics of eligible studies included

Author Year Controltype Nationality Ethnicity Disease Control Case P for HWE Score Genotyping method
A-1082G Total AA AG GG Total AA AG GG
Peddireddy et al31 2016 HB India Asians NSCLC 250 130 84 36 246 156 69 21 <0.05 7 PCR-RFLP
Hsia et al32 2014 HB People’s Republic of China Asians Lung neoplasms 716 561 130 25 358 273 69 16 <0.05 7 PCR-RFLP
Hart et al34 2011 HB Norway Caucasians NSCLC 435 104 226 105 436 120 207 109 0.41 7 TaqMan
Hao et al37 2009 HB People’s Republic of China Asians Lung neoplasms 52 46 6 44 36 7 0.99 8 TaqMan
Colakogullari et al30 2007 HB Turkey Caucasians Lung neoplasms 59 33 21 5 44 11 30 3 0.53 7 PCR-SSP
Shih et al28 2005 HB People’s Republic of China Asians NSCLC 205 194 11 0 154 115 39 0 0.69 8 PCR-RFLP
Seifart et al29 2005 HB Germany Caucasians Lung neoplasms 243 86 115 42 39 6 21 12 0.74 7 PCR-RFLP
A-592C Total CC CA AA Total CC CA AA
Zhang et al33 2015 HB People’s Republic of China Asians Lung neoplasms 336 75 176 85 330 110 156 64 0.37 7 PCR-RFLP
Hsia et al32 2014 HB People’s Republic of China Asians Lung neoplasms 716 71 277 368 358 40 145 173 0.08 7 PCR-RFLP
Hart et al34 2011 HB Norway Caucasians NSCLC 433 243 175 15 434 264 144 26 <0.05 7 TaqMan
Liang et al35 2011 HB People’s Republic of China Asians NSCLC 120 7 44 69 116 11 36 69 0.99 8 PCR-RFLP
Vogel et al36 2008 PB Denmark Caucasians NSCLC 744 452 250 42 403 241 149 13 0.34 8 PCR-RFLP
Colakogullari et al30 2007 HB Turkey Caucasians Lung neoplasms 59 27 25 7 44 19 23 2 0.74 7 PCR-SSP
Shih et al28 2005 HB People’s Republic of China Asians NSCLC 205 13 76 116 154 18 70 66 0.91 8 PCR-RFLP
T-819C Total TT TC CC Total TT TC CC
Zhang et al33 2015 HB People’s Republic of China Asians Lung neoplasms 336 145 144 47 330 108 135 87 0.25 7 PCR-RFLP
Hsia et al32 2014 HB People’s Republic of China Asians Lung neoplasms 716 372 265 79 358 212 128 18 <0.05 7 PCR-RFLP
Colakogullari et al30 2007 HB Turkey Caucasians Lung neoplasms 59 7 26 26 44 2 23 19 0.9 7 PCR-SSP
Shih et al28 2005 HB People’s Republic of China Asians NSCLC 205 104 86 15 154 66 58 30 0.63 8 PCR-RFLP
Seifart et al29 2005 HB Germany Caucasians Lung neoplasms 242 14 88 140 40 2 14 24 0.97 7 PCR-RFLP
Open in a new tab

Abbreviations: HB, control hospital based; PB, control population based; NSCLC, non-small-cell lung cancer; PCR, polymerase chain reaction; RFLP, restricted fragment length polymorphism; SSP, sequence specific primer.

Figure 1.

Figure 1

Open in a new tab

Flow diagram of the search literature.

Quantitative analysis

A total of 10 publications amounting to 19 case–control studies were included in this meta-analysis. In the overall analysis, the presence of IL-10 -1082A/G polymorphisms was associated with increased lung cancer risk, while IL-10 -592C/A polymorphisms were shown to decrease the lung cancer risk (for A-1082G, A vs G, OR =1.17, CI =1.04–1.30, P<0.05; AA vs [AG + GG], OR =1.21, CI =1.05–1.40, P<0.05; for C-592A, C vs A, OR =0.84, CI =0.77–0.91, P<0.05; CC vs AA, OR =0.74, CI =0.64–087, P<0.05; CC vs [CA + AA], OR =0.83, CI =0.74–0.94, P<0.05; [CC + CA] vs AA, OR =0.79, CI =0.69–0.91, P<0.05). When stratified by ethnicity, IL-10 -1082A/G, C-592A, and T-819C polymorphisms were associated with increased lung cancer risk in Asians (for -1082A/G, AA vs [AG + GG]: OR =1.20, CI =1.05–1.39, P<0.05; for C-592A, C vs A, OR =1.36, CI =1.20–1.53, P<0.05; CC vs AA, OR =1.85, CI =1.45–2.37, P<0.05; CC vs [CA + AA], OR =1.36, CI =1.15–1.61, P<0.05; for -819T/C, T vs C: OR =1.21, CI =1.06–1.38, P<0.05; TT vs CC, OR =1.54, CI =1.18–2.01, P<0.05; [TT + TC] vs CC, OR =1.51, CI =1.17–1.95, P<0.05). Furthermore, when stratified based on disease type, a significant correlation was detected between IL-10 T-819C polymorphism and non-small-cell lung cancer (NSCLC; for -819T/C, T vs C: OR =1.57, CI =1.15–2.16, P<0.05; TT vs CC, OR =3.15, CI =1.58–6.30, P<0.05; [TT + TC] vs CC, OR =3.07, CI =1.58–5.93, P<0.05). Interestingly, no significant association between IL-10 -1082A/G, C-592A, and T-819C polymorphisms and lung cancer risk was found in Caucasians. Furthermore, significantly decreased risk of lung cancer risk was found in the overall analysis of C-592A polymorphism, whereas significantly increased risk was detected in the Asian population (Table 2).

Table 2.

Meta-analysis results of the association between IL-10 -1082A/G, -592C/A, and -819T/C polymorphisms and lung cancer risk

IL-10 Allele model
Homozygous model
Dominant model
Recessive model
OR/95% CI P-value OR/95% CI P-value OR/95% CI P-value OR/95% CI P-value
A-1082G A vs G AA vs GG AA vs (AG + GG) (AA + AG) vs GG
Caucasians 1.37 (0.98–1.35) 0.08 1.33 (0.97–1.83) 0.08 1.21 (0.94–1.55) 0.14 1.21 (0.92–1.58) 0.17
Asians 1.14 (0.96–1.36) 0.14 0.99 (0.65–1.51) 0.95 1.20 (1.05–1.39) <0.05 1.15 (0.92–1.43) 0.21
NSCLC 1.02 (0.89–1.18) 0.75 1.01 (0.77–1.33) 0.95 1.05 (0.87–1.27) 0.58 0.98 (0.76–1.27) 0.87
Total 1.17 (1.04–1.30) <0.05 1.23 (0.98–1.54) 0.07 1.21 (1.05–1.40) <0.05 1.15 (0.92–1.43) 0.21
C-592A C vs A CC vs AA CC vs (CA + AA) (CC + CA) vs AA
Caucasians 0.96 (0.83–1.11) 0.55 0.88 (0.59–1.33) 0.55 0.96 (0.80–1.14) 0.62 0.89 (0.60–1.34) 0.58
Asians 1.36 (1.20–1.53) <0.05 1.85 (1.45–2.37) <0.05 1.36 (1.15–1.61) <0.05 0.74 (0.62–0.87) <0.05
NSCLC 0.98 (0.87–1.10) 0.70 0.96 (0.77–1.21) 0.74 0.98 (0.84–1.14) 0.75 0.97 (0.79–1.20) 0.79
Total 0.84 (0.77–0.91) <0.05 0.74 (0.64–0.87) <0.05 0.83 (0.74–0.94) <0.05 0.79 (0.69–0.91) <0.05
T-819C T vs C TT vs CC TT vs (TC + CC) (TT + TC) vs CC
Caucasians 0.96 (0.65–1.41) 0.82 1.36 (0.44–4.17) 0.59 1.50 (0.50–4.50) 0.47 0.85 (0.53–1.38) 0.52
Asians 1.21 (1.06–1.38) <0.05 1.54 (1.18–2.01) <0.05 1.15 (0.97–1.37) 0.11 1.51 (1.17–1.95) <0.05
NSCLC 1.57 (1.15–2.16) <0.05 3.15 (1.58–6.30) <0.05 1.37 (0.90–2.09) 0.14 3.07 (1.58–5.93) <0.05
Total 0.97 (0.86–1.10) 0.63 0.95 (0.76–1.20) 0.68 0.96 (0.82–1.14) 0.66 0.97 (0.79–1.19) 0.77
Open in a new tab

Abbreviations: NSCLC, non-small-cell lung cancer; OR, odds ratio; 95% CI, 95% confidence interval.

Heterogeneity analysis

Under the homozygous genetic models, significant heterogeneity existed among the studies on IL-10 -1082A/G and -819T/C polymorphisms (for 1082A/G, I2=71.8%, P=0.007; for -819T/C, I2=88.0%, P=0.000). The forest plots suggested that ethnicity and disease type might be one of the sources of heterogeneity for IL-10 -1082A/G and -819T/C polymorphisms. However, heterogeneity was significantly lowered after the subgroup analyses based on ethnicity and disease type were conducted. This indicated that the ethnicity and disease type might lead to the heterogeneity. Furthermore, a meta-regression revealed that score, sample size, and genotyping method were not the sources of heterogeneity (for IL-10 -1082A/G and -819T/C, P>0.05; Figures 2–4).

Figure 2.

Figure 2

Open in a new tab

Forest plot of lung cancer risk associated with IL-10 -1082A/G (AA vs GG) polymorphism stratified by ethnicity. Note: Weights are from random effects analysis.

Figure 3.

Figure 3

Open in a new tab

Forest plot of lung cancer risk associated with IL-10 C-592A (CC vs AA) polymorphism stratified by ethnicity.

Figure 4.

Figure 4

Open in a new tab

Forest plot of lung cancer risk associated with IL-10 -819T/C (TT vs CC) polymorphism stratified by ethnicity. Note: Weights are from random effects analysis.

Publication bias and sensitivity analysis

On the basis of the Begg’s test and Egger’s test, no publication bias was found for the association between IL-10 -1082A/G, -592C/A, and -819T/C polymorphisms and lung cancer risk. Moreover, sensitivity analysis indicated that the results were stable after sequentially omitting each study (Figures 5–7).

Figure 5.

Figure 5

Open in a new tab

Begg’s funnel plot with pseudo 95% confidence limits for studies of the association between lung cancer risk and IL-10 -1082A/G (AA vs GG) polymorphism.

Abbreviation: SE, standard error.

Figure 6.

Figure 6

Open in a new tab

Begg’s funnel plot with pseudo 95% confidence limits for studies of the association between lung cancer risk and IL-10 C-592A (CC vs AA) polymorphism.

Abbreviation: SE, standard error.

Figure 7.

Figure 7

Open in a new tab

Begg’s funnel plot with pseudo 95% confidence limits for studies of the association between lung cancer risk and IL-10 -819T/C (TT vs CC) polymorphism.

Abbreviation: SE, standard error.

Discussion

IL-10 was shown to have a significant effect on the tumorigenesis of different cancers and could even protect tumors by inhibiting the function of macrophages and dendritic cells, which present tumor cell antigens to the cytotoxic T lymphocytes.15 Previous studies have found an association between IL-10 polymorphism and oral cancer, breast cancer, gastric cancer, colorectal cancer, esophageal cancer, hepatocellular cancer, cervical cancer, thyroid cancer, and nasopharyngeal cancer.16–24 As for lung cancer, many studies have revealed that the loss of IL-10 expression could promote progression and poor clinical outcomes of lung cancer; however, the opposite effects were also found in some patients.25 Interestingly, the absence of IL-10 had opposite effects on the early and late stages of NSCLC.26 Hence, the expression or polymorphisms of IL-10 gene might serve as a good indicator of susceptibility and prognostic outcome for lung cancer in different stages of the disease.27 These lung cancer biomarkers might be used for screening, early detection, early diagnosis, prognosis, prediction, stratification, and therapy response monitoring.3 Although previous case–control studies showed that the IL-10 polymorphism might contribute to the risk of lung cancer, and the sample size of the studies was too small. Thus, this meta-analysis was performed.

Through this comprehensive meta-analysis, the association between IL-10 -1082A/G, -592C/A, and -819T/C polymorphism and the risk of lung cancer was evaluated. To our knowledge, this is the first systematic meta-analysis to date that deals with the association between IL-10 -1082A/G, -592C/A, and -819T/C polymorphisms and lung cancer risk. In the overall analysis, we found that IL-10 -1082A/G, -592C/A, and -819T/C polymorphisms were significantly associated with lung cancer risk. Interestingly, IL-10 -1082A/G, -592C/A, and -819T/C polymorphisms were significantly associated with lung cancer risk in Asians, but not in the Caucasians. Furthermore, the results indicated that individuals who carried the IL-10 -1082G allele had an increased risk of lung cancer, and those with the IL-10 -819T allele were shown to have a decreased risk of lung cancer compared to those with the -819C allele. The results of previous case–control studies by Shih et al,28 Seifart et al,29 Colakogullari et al,30 and Peddireddy et al31 for IL-10 -1082A/G polymorphism were consistent with this meta-analysis and indicated that the IL-10 -1082A/G polymorphism could increase the risk of lung cancer. The results of Hsia et al,32 Shih et al,28 and Zhang et al33 for IL-10 -819T/C polymorphism showed that IL-10 -819T/C polymorphism was significantly associated with an increased risk of lung cancer. Nevertheless, different results were also found in the studies of Hsia et al32 and Hart et al34 concerning the IL-10 -1082A/G polymorphism. However, several of the included studies showed no significant correlation of IL-10 A-592C and -819T/C polymorphisms with lung cancer risk.29,30,32,34–36 In addition, there was adequate evidence indicating the different frequency distribution of IL-10 -592C/A and -819T/C allele between Asians and Caucasians in the meta-analysis. And this result was consistent with the data given in the HapMap database. Thus, a decreased risk of lung cancer in Caucasians and an increased risk of lung cancer in Asians was associated with the IL-10 -592C/A and -819T/C polymorphisms, although no significant association of IL-10 -592C/A and -819T/C polymorphisms with lung cancer risk in Caucasians was found. In addition, based on the results of the subgroup analysis, we found that IL-10 -819T/C polymorphism was associated with susceptibility to NSCLC. A previous study reported that IL-10 might be involved in the process of tumor escape from the immune response, and increased production of IL-10 has been shown to correlate with the survival of NSCLC patients.28 However, only one study was included in the subgroup analysis, and this lowered the statistical power. For the IL-10 -1082A/G and -592C/A polymorphism, no significant correlation with NSCLC risk was detected. The analysis of small-cell lung cancer was not performed because the sample of small-cell lung cancer was too small and the classification of small-cell lung cancer was not clear. On the basis of the meta-analysis, to a large extent, there was no significant association between IL-10 -1082A/G, -592C/A polymorphism and NSCLC risk. To confirm this conclusion, studies with larger sample number must be conducted. The study results showed that subgroup analysis is very important for a systematic review and meta-analysis. From the studies included, there is evidence that the association between IL-10 polymorphism and lung cancer risk is still not clear. Therefore, performing a meta-analysis and systematic review was necessary to clarify this relevance. These results are shown in Figure 3.

Limitations

Several limitations of this meta-analysis should be acknowledged. First, the small number of eligible studies might limit the meta-analysis. There were only five or seven studies available for three SNPs of IL-10 gene in the stratification analysis in particular, which might have attenuated the statistical power of the meta-analysis. Second, the missing individual data, for example, cancer stage and cancer subtype might also have an impact on the interpretation. Third, this meta-analysis could not address the gene–environmental interactions in the correlation of IL-10 polymorphism with lung cancer risk. The conclusions only depend on the ORs, which might lead to confounding bias. Finally, the inclusion of data that was inconsistent with HWE might affect the accuracy of the results. However, the large sample size could weaken the impact of the association of IL-10 polymorphism with lung cancer risk.

In conclusion, this meta-analysis of ten case–control studies suggested that the IL-10 -1082A/G, -592C/A, and -819T/C polymorphisms were associated with the increased risk of lung cancer in Asians. Nevertheless, considering the limitations of the study, further large-scale, well-designed, and population-based studies are still needed to assess the correlation between IL-10 polymorphism and lung cancer risk.

Acknowledgments

The authors would like to thank all the participants involved in the research.

Footnotes

Disclosure

The authors report no conflicts of interest in this work.

References

  • 1.Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90. doi: 10.3322/caac.20107. [DOI] [PubMed] [Google Scholar]
  • 2.IAFROC. WHO. GLOBOCAN 2012 . Estimated cancer incidence, mortality and prevalence worldwide in 2012: liver cancer. [Google Scholar]
  • 3.Chen W, Zhang S, Zou X. Evaluation on the incidence, mortality and tendency of lung cancer in China. Thoracic Cancer. 2010;1:35–40. doi: 10.1111/j.1759-7714.2010.00011.x. [DOI] [PubMed] [Google Scholar]
  • 4.I H, Cho JY. Lung cancer biomarkers. Adv Clin Chem. 2015;72:107–170. doi: 10.1016/bs.acc.2015.07.003. [DOI] [PubMed] [Google Scholar]
  • 5.Khuder SA. Effect of cigarette smoking on major histological types of lung cancer: a meta-analysis. Lung Cancer. 2001;31:139–148. doi: 10.1016/s0169-5002(00)00181-1. [DOI] [PubMed] [Google Scholar]
  • 6.Kowgier M, Qiu LA, Tse H. Surgery for small cell lung cancer. Asian Pac J Surg Oncol. 2015;1:171–180. [Google Scholar]
  • 7.Wang S, Lan X, Tan S, Wang S, Li Y. P53 codon 72 Arg/Pro polymorphism and lung cancer risk in Asians: an updated meta-analysis. Tumour Biol. 2013;34:2511–2520. doi: 10.1007/s13277-013-0678-2. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Sandri A, Brunelli A, Rzyman W, et al. Pathology of non-small cell lung cancer and small cell lung cancer. Asian Pac J Surg Oncol. 2015;1:113–124. [Google Scholar]
  • 9.Brooks DG, Trifilo MJ, Edelmann KH, Teyton L, McGavern DB, Oldstone MB. Interleukin-10 determines viral clearance or persistence in vivo. Nat Med. 2006;12:1301–1309. doi: 10.1038/nm1492. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Kim R, Emi M, Tanabe K, Arihiro K. Tumor-driven evolution of immunosuppressive networks during malignant progression. Cancer Res. 2006;66:5527–5536. doi: 10.1158/0008-5472.CAN-05-4128. [DOI] [PubMed] [Google Scholar]
  • 11.Rausch SM, Gonzalez BD, Clark MM, et al. SNPs in PTGS2 and LTA predict pain and quality of life in long term lung cancer survivors. Lung Cancer. 2012;77:217–223. doi: 10.1016/j.lungcan.2012.02.017. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Stearns ME, Rhim J, Wang M. Interleukin 10 (IL-10) inhibition of primary human prostate cell-induced angiogenesis: IL-10 stimulation of tissue inhibitor of metalloproteinase-1 and inhibition of matrix metalloproteinase (MMP)-2/MMP-9 secretion. Clin Cancer Res. 1999;5:189–196. [PubMed] [Google Scholar]
  • 13.DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177–188. doi: 10.1016/0197-2456(86)90046-2. [DOI] [PubMed] [Google Scholar]
  • 14.Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22:719–748. [PubMed] [Google Scholar]
  • 15.Goncalves AS, Arantes DA, Bernardes VF, et al. Immunosuppressive mediators of oral squamous cell carcinoma in tumour samples and saliva. Hum Immunol. 2015;76:52–58. doi: 10.1016/j.humimm.2014.11.002. [DOI] [PubMed] [Google Scholar]
  • 16.Hsu HJ, Yang YH, Shieh TY, et al. Role of cytokine gene (interferon-gamma, transforming growth factor-beta1, tumor necrosis factor-alpha, interleukin-6, and interleukin-10) polymorphisms in the risk of oral precancerous lesions in Taiwanese. Kaohsiung J Med Sci. 2014;30:551–558. doi: 10.1016/j.kjms.2014.09.003. [DOI] [PubMed] [Google Scholar]
  • 17.Tsai CW, Tsai MH, Shih LC, Chang WS, Lin CC, Bau DT. Association of interleukin-10 (IL10) promoter genotypes with nasopharyngeal carcinoma risk in Taiwan. Anticancer Res. 2013;33:3391–3396. [PubMed] [Google Scholar]
  • 18.Wang Z, Liu QL, Sun W, et al. Genetic polymorphisms in inflammatory response genes and their associations with breast cancer risk. Croat Med J. 2014;55:638–646. doi: 10.3325/cmj.2014.55.638. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Yu T, Lu Q, Ou XL, Cao DZ, Yu Q. Clinical study on gastric cancer susceptibility genes IL-10-1082 and TNF-alpha. Genet Mol Res. 2014;13:10909–10912. doi: 10.4238/2014.December.19.12. [DOI] [PubMed] [Google Scholar]
  • 20.Miteva LD, Stanilov NS, Deliysky TS, Stanilova SA. Significance of -1082A/G polymorphism of IL10 gene for progression of colorectal cancer and IL-10 expression. Tumour Biol. 2014;35:12655–12664. doi: 10.1007/s13277-014-2589-2. [DOI] [PubMed] [Google Scholar]
  • 21.Sakamoto K, Oka M, Yoshino S, et al. Relationship between cytokine gene polymorphisms and risk of postoperative pneumonia with esophageal cancer. J Gastrointest Surg. 2014;18:1247–1253. doi: 10.1007/s11605-014-2531-3. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Pan D, Zeng X, Yu H, et al. Role of cytokine gene polymorphisms on prognosis in hepatocellular carcinoma after radical surgery resection. Gene. 2014;544:32–40. doi: 10.1016/j.gene.2014.04.042. [DOI] [PubMed] [Google Scholar]
  • 23.Zhang X, Zhang L, Tian C, Yang L, Wang Z. Genetic variants and risk of cervical cancer: epidemiological evidence, meta-analysis and research review. BJOG. 2014;121:664–674. doi: 10.1111/1471-0528.12638. [DOI] [PubMed] [Google Scholar]
  • 24.Cil E, Kumral A, Kanmaz-Ozer M, et al. Interleukin-10-1082 gene polymorphism is associated with papillary thyroid cancer. Mol Biol Rep. 2014;41:3091–3097. doi: 10.1007/s11033-014-3169-7. [DOI] [PubMed] [Google Scholar]
  • 25.Wang R, Lu M, Zhang J, et al. Increased IL-10 mRNA expression in tumor-associated macrophage correlated with late stage of lung cancer. J Exp Clin Cancer Res. 2011;30:62. doi: 10.1186/1756-9966-30-62. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.De Vita F, Orditura M, Galizia G, et al. Serum interleukin-10 levels as a prognostic factor in advanced non-small cell lung cancer patients. Chest. 2000;117:365–373. doi: 10.1378/chest.117.2.365. [DOI] [PubMed] [Google Scholar]
  • 27.Hatanaka H, Abe Y, Kamiya T, et al. Clinical implications of interleukin (IL)-10 induced by non-small-cell lung cancer. Ann oncol. 2000;11:815–819. doi: 10.1023/a:1008375208574. [DOI] [PubMed] [Google Scholar]
  • 28.Shih CM, Lee YL, Chiou HL, et al. The involvement of genetic polymorphism of IL-10 promoter in non-small cell lung cancer. Lung Cancer. 2005;50:291–297. doi: 10.1016/j.lungcan.2005.07.007. [DOI] [PubMed] [Google Scholar]
  • 29.Seifart C, Plagens A, Dempfle A, et al. TNF-alpha, TNF-beta, IL-6, and IL-10 polymorphisms in patients with lung cancer. Dis Markers. 2005;21:157–165. doi: 10.1155/2005/707131. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Colakogullari M, Ulukaya E, Yilmaztepe OA, et al. The involvement of IL-10, IL-6, IFN-gamma, TNF-alpha and TGF-beta gene polymorphisms among Turkish lung cancer patients. Cell Biochem Funct. 2011;26:283–290. doi: 10.1002/cbf.1419. [DOI] [PubMed] [Google Scholar]
  • 31.Peddireddy V, Badabagni SP, Sulthana S, Kolla VK, Gundimeda SD, Mundluru H. Association of TNFalpha-308, IFNgamma+874, and IL10-1082 gene polymorphisms and the risk of non-small cell lung cancer in the population of the South Indian state of Telangana. Int J Clin Oncol. 2016 doi: 10.1007/s10147-016-0972-2. Epub ahead of print. [DOI] [PubMed] [Google Scholar]
  • 32.Hsia TC, Chang WS, Liang SJ, et al. Interleukin-10 (IL-10) promoter genotypes are associated with lung cancer risk in Taiwan males and smokers. Anticancer Res. 2014;34:7039–7044. [PubMed] [Google Scholar]
  • 33.Zhang YM, Mao YM, Sun YX. Genetic polymorphisms of IL-6 and IL-10 genes correlate with lung cancer in never-smoking Han population in China. Int J Clin Exp Med. 2015;8:1051–1058. [PMC free article] [PubMed] [Google Scholar]
  • 34.Hart K, Landvik NE, Lind H, Skaug V, Haugen A, Zienolddiny S. A combination of functional polymorphisms in the CASP8, MMP1, IL10 and SEPS1 genes affects risk of non-small cell lung cancer. Lung Cancer. 2011;71:123–129. doi: 10.1016/j.lungcan.2010.04.016. [DOI] [PubMed] [Google Scholar]
  • 35.Liang HG, Fu SR, Qi XM. Relationship between the genetic polymorphism in Interleukin-10 -592C/A and susceptibility to non-small cell lung cancer. China J Modern Med. 2011;21:189–193. Article in Chinese. [Google Scholar]
  • 36.Vogel U, Christensen J, Wallin H, et al. Polymorphisms in genes involved in the inflammatory response and interaction with NSAID use or smoking in relation to lung cancer risk in a prospective study. Mutat Res. 2008;639:89–100. doi: 10.1016/j.mrfmmm.2007.11.004. [DOI] [PubMed] [Google Scholar]
  • 37.Hao MG, Wang WJ, Lu Y, et al. Association of genetic polymorphism within promoter region of TNF-α, IL-1β and IL-10 with the susceptibility to lung cancer. J Environ Occup Med. 2009;26:24–27. Chinese. [Google Scholar]

Articles from OncoTargets and therapy are provided here courtesy of Dove Press

RESOURCES